Yahoo Finance

BofA lowered the firm’s price target on Myriad Genetics (MYGN) to $9 from $11 and keeps an Underperform rating on the shares. Sentiment for Life Sciences and Diagnostic Tools and Contract Research Organizations is “particularly negative” heading into earnings given that these companies “sit at the intersection of a number of policy changes from the Trump Administration,” including headwinds from NIH budget cuts and global tariffs, as well as broader macro concerns, especially around China, the analyst tells investors in a preview for the group.

Stay Ahead of the Market:

• Discover outperforming stocks and invest smarter with Top Smart Score Stocks.

• Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on MYGN:

Disclaimer & DisclosureReport an Issue

• Myriad Genetics downgraded to Neutral from Buy at Guggenheim

• Myriad Genetics appoints Brian Donnelly as CCO

• Myriad Genetics price target lowered to $20 from $24 at Scotiabank

• Buy Rating on Myriad Genetics: Strategic Changes and Growth Potential Amid Challenges

• Myriad Genetics upgraded to Overweight from Neutral at Piper Sandler